Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan
Bin Chang,Kosuke Tamura,Hiroyuki Fujikura,Hiroshi Watanabe,Yoshinari Tanabe,Koji Kuronuma,Jiro Fujita,Kengo Oshima,Takaya Maruyama,Shuichi Abe,Kei Kasahara,Junichiro Nishi,Tetsuya Kubota,Yuki Kinjo,Yusuke Serizawa,Reiko Shimbashi,Munehisa Fukusumi,Tomoe Shimada,Tomimasa Sunagawa,Motoi Suzuki,Kazunori Oishi,Adult IPD Study Group,Kenji Gotoh,Chikako Tsubata,Hiroki Takahashi,Tetsuji Aoyagi,Masashi Nakamatsu,Naoko Imuta,Akihito Yokoyama,Hiroaki Takeda,Masayuki Ishida
DOI: https://doi.org/10.1038/s41598-022-06950-w
2022-02-23
Abstract:We assessed the impact of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis in adults in Japan in 2014-2018 by comparing epidemiological characteristics of adults with invasive pneumococcal disease with (n = 222) and without (n = 1258) meningitis. The annual incidence of pneumococcal meningitis in 2016-2018 was 0.20-0.26 cases/100,000 population. Age (p < 0.001) and case fatality rate (p = 0.003) were significantly lower in patients with meningitis than in those without meningitis. The odds of developing meningitis were higher in asplenic/hyposplenic or splenectomized patients (adjusted odds ratio [aOR] 2.29, 95% CI 1.27-4.14), for serotypes 10A (aOR 3.26, 95% CI 2.10-5.06) or 23A (aOR 3.91, 95% CI 2.47-6.19), but lower for those aged ≥ 65 years (aOR 0.59, 95% CI 0.44-0.81). PCV13 had an indirect effect on nonmeningitis, but its impact on meningitis was limited because of an increase in non-PCV13 serotypes. Of meningitis isolates, 78 (35.1%) and 3 (1.4%) were penicillin G- or ceftriaxone-resistant, respectively. We also confirmed an association of the pbp1bA641C mutation with meningitis (aOR 2.92, 95% CI 1.51-5.65).